SCHEMBL31246552

SCHEMBL31246552

Cn1ccc2ccnc(N(C(=O)N3Cc4ccc(C#N)cc4C3)[C@@H]3CCCNC3)c21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPLP1 P05386 14/20 0.63
RPLP0 P05388 14/20 0.63
RPS17 P08708 14/20 0.63
RPSA P08865 14/20 0.63
RPS2 P15880 14/20 0.63
RPL35A P18077 14/20 0.63
RPL7 P18124 14/20 0.63
RPL17 P18621 14/20 0.63
RPS4Y1 P22090 14/20 0.63
RPS3 P23396 14/20 0.63
RPS12 P25398 14/20 0.63
RPL13 P26373 14/20 0.63
RPL10 P27635 14/20 0.63
RPL12 P30050 14/20 0.63
RPL9; RPL9P7; RPL9P8; RPL9P9 P32969 14/20 0.63
RPL22 P35268 14/20 0.63
RPL4 P36578 14/20 0.63
RPS19 P39019 14/20 0.63
RPL3 P39023 14/20 0.63
RPL13A P40429 14/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31246886 0.83 RPLP1 (0.80) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31247185 0.80 RPLP1 (0.65) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31247174 0.80 RPLP1 (0.77) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31246631 0.79 KCNH2 (0.52) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31246568 0.78 RPLP1 (0.55) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31246624 0.78 RPLP1 (0.72) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31246572 0.78 RPLP1 (0.75) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31246493 0.78 KCNH2 (0.54) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31246964 0.77 RPLP1 (1.00) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL31247233 0.77 RPLP1 (0.73) RPLP1RPLP0RPS17RPSARPS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 RPLP1 196/4885RPLP0 763/4885RPS17 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.